CaReS®

Ars Arthro AG (Esslingen) received approval (8th July) to the IND application for the clinical application of the Cartilage-Regeneration Technology CaReS® in the US-American market from the American Food and Drug Administration (FDA).

CaReS® is an innovative cartilage cell regeneration procedure. Using a 3D-Collagen-Gel-Matrix an individual pressure and form-stable transplant is developed in only 10 to 14 days. This can be adapted to the individual defect size prior to operation. The transplant is fixed with with fibrin glue; this avoids the creation of fixation seams that are unavoidable with ACT. This reduces operation time substantially and the exposure of the surrounding joint cartilage. The result: fast, long-term and optimised healing of large cartilage lesions on the knee, foot and ankle through the first safe transplantation of a defined quantity of controllable autologous cells.